Diabetes

Use of glucagon-like peptide-1 receptor agonists was associated with a reduced risk for progression to cirrhosis and other complications in patients with metabolic dysfunction-associated steatotic liver disease and diabetes, data showed.

Patients with type 2 diabetes and more severe peripheral neuropathy appeared to be at greater risk for developing dry eye disease, according to a study published in Optometry and Vision Science.

In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported.

The FDA has cleared a continuous glucose monitoring system with an implantable sensor that can be worn for up to 1 year for adults aged 18 years and older with type 1 or type 2 diabetes, according to a press release.

The use of glucagon-like peptide-1 receptor agonists exponentially increased in recent years for treating diabetes and obesity, with benefits also observed in other cardiometabolic syndromes.

The explosive popularity of glucagon-like peptide-1 receptor agonists for diabetes and weight loss may have revolutionized obesity management, but their widespread use has also sparked concerns — and ignited a turf war — in the endoscopy suite.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.

Nearly one in 20 adults in the U.S. are estimated to have atrial fibrillation, many more than previous studies had indicated, according to new data out of the University of California, San Francisco.

Country-specific public health policies that target metabolic dysfunction-associated steatotic liver disease risk factors, such as food insecurity and physical activity, may play a key role in mitigating the global burden of disease.

Once-weekly insulin efsitora alfa provided similar reductions in HbA1c as once-daily insulin degludec among insulin-naive adults with type 2 diabetes and adults with type 1 diabetes previously receiving a basal and bolus insulin analog.